Filing Details

Accession Number:
0001209191-18-046476
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-08-13 17:41:30
Reporting Period:
2018-08-09
Accepted Time:
2018-08-13 17:41:30
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1724521 Arcus Biosciences Inc. RCUS () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1422996 C. Juan Jaen 3928 Point Eden Way
Hayward CA 94545
President Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-08-09 4,262 $11.93 2,738,502 No 4 P Indirect By Trust
Common Stock Acquisiton 2018-08-10 2,579 $11.94 2,741,081 No 4 P Indirect By Trust
Common Stock Acquisiton 2018-08-13 3,159 $11.77 2,744,240 No 4 P Indirect By Trust
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By Trust
No 4 P Indirect By Trust
No 4 P Indirect By Trust
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 189,393 Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.41 to $12.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.87 to $12.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.61 to $11.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.